Video

Dr. Johnson on the Promise of DS-7300 in SCLC and Other Advanced Solid Tumors

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors.

Melissa L. Johnson, MD, program director, Lung Cancer Research, lead, Solid Tumor Immune Effector Cellular Therapy Program, Sarah Cannon Research Institute, discusses the promise of DS-7300 in small cell lung cancer (SCLC) and other advanced solid tumors.

During the 2021 ESMO Congress, findings from a phase 1/2 trial (NCT04145622) were presented. The study is evaluating the safety and initial efficacy of DS-7300. The antibody-drug conjugate (ADC) is directed toward B7 homologue 3 (B7-H3), which is a transmembrane protein overexpressed in several cancers, such as lung, prostate, esophageal, breast, and head and neck cancers. The ADC utilizes a topoisomerase I inhibitor payload as its mechanism of action.

Among 70 patients who received various dosing levels of DS-7300, 15 derived a partial response with the agent. Responses were observed in patients with prostate cancer, SCLC, and esophageal squamous cell carcinoma, Johnson explains.

Notably, because B7-H3 is an immune checkpoint, knowledge generated in oncology with immunotherapy and other ADCs may inform the utility of DS-7300, Johnson concludes.


Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity